CMA
GBT

Cedar Mountain Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Cedar Mountain Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1
Closed – – 302
2020
Q4 		$0 Hold
1
– – ﹤0.01% 283
2020
Q3 		$0 Buy
+1
New +$64 ﹤0.01% 274

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cedar Mountain Advisors's GBT Position: Q1 2021 in Review

Cedar Mountain Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 1 share.

Cedar Mountain Advisors first reported a position in GBT in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2020. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

  • Cedar Mountain Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Cedar Mountain Advisors sold 1 Global Blood Therapeutics, Inc. share in Q1 2021.
  • Cedar Mountain Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
  • Cedar Mountain Advisors's Global Blood Therapeutics, Inc. position peaked at $0 in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on Cedar Mountain Advisors's 13F filing for Q1 2021, filed 23 Apr 2021.